JP2002524456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524456A5 JP2002524456A5 JP2000568841A JP2000568841A JP2002524456A5 JP 2002524456 A5 JP2002524456 A5 JP 2002524456A5 JP 2000568841 A JP2000568841 A JP 2000568841A JP 2000568841 A JP2000568841 A JP 2000568841A JP 2002524456 A5 JP2002524456 A5 JP 2002524456A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- patient
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 37
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 230000004968 inflammatory condition Effects 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical group CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1cc(*)c(*)c(C)c1C(CC1)COC1=O Chemical compound Cc1cc(*)c(*)c(C)c1C(CC1)COC1=O 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- -1 methoxy, ethoxy, propoxy, cyclopentyloxy, cyclohexyloxy Chemical group 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- MUNMIGOEDGHVLE-LGYYRGKSSA-N ornipressin Chemical compound NC(=O)CNC(=O)[C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 MUNMIGOEDGHVLE-LGYYRGKSSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9963798P | 1998-09-09 | 1998-09-09 | |
| US12150799P | 1999-02-23 | 1999-02-23 | |
| US14951799P | 1999-08-17 | 1999-08-17 | |
| US60/149,517 | 1999-08-17 | ||
| US60/121,507 | 1999-08-17 | ||
| US60/099,637 | 1999-08-17 | ||
| PCT/CA1999/000819 WO2000014083A1 (en) | 1998-09-09 | 1999-09-09 | SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002524456A JP2002524456A (ja) | 2002-08-06 |
| JP2002524456A5 true JP2002524456A5 (enExample) | 2006-11-02 |
| JP4979157B2 JP4979157B2 (ja) | 2012-07-18 |
Family
ID=27378872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568841A Expired - Fee Related JP4979157B2 (ja) | 1998-09-09 | 1999-09-09 | 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6458829B1 (enExample) |
| EP (1) | EP1112262B1 (enExample) |
| JP (1) | JP4979157B2 (enExample) |
| AT (1) | ATE272628T1 (enExample) |
| AU (1) | AU757052B2 (enExample) |
| CA (1) | CA2343732C (enExample) |
| DE (1) | DE69919179T2 (enExample) |
| ES (1) | ES2226422T3 (enExample) |
| WO (1) | WO2000014083A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770658B2 (en) * | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US9931318B2 (en) * | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| US20040224316A1 (en) | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
| US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| KR100439425B1 (ko) * | 2001-03-22 | 2004-07-05 | (주)바이오케어 | 잔토리졸을 포함하는 조성물 및 그 용도 |
| KR20040007583A (ko) * | 2001-05-23 | 2004-01-24 | 다나베 세이야꾸 가부시키가이샤 | 연골 질환의 재생치료용 조성물 |
| US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US7642252B2 (en) * | 2002-07-22 | 2010-01-05 | Chemgenex Pharmaceuticals, Inc. | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| EP2177626B1 (en) | 2002-08-19 | 2013-12-18 | Dart NeuroScience (Cayman) Ltd | Screening methods for cognitive enhancers |
| ES2213485B1 (es) * | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
| JP2007526460A (ja) * | 2004-03-03 | 2007-09-13 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 |
| WO2006086693A2 (en) * | 2005-02-10 | 2006-08-17 | Chemgenex Pharmaceuticals, Inc. | Medical devices |
| US20080171746A1 (en) * | 2005-03-14 | 2008-07-17 | Thomas Klein | Method for Preventing Cardiovascular Diseases |
| EP2377533A3 (en) | 2006-05-19 | 2012-02-22 | Helicon Therapeutics, Inc. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| AR065709A1 (es) * | 2007-03-12 | 2009-06-24 | Biolipox Ab | Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion. |
| GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| AU2008240044B2 (en) * | 2007-04-13 | 2013-09-12 | Teva Pharamceuticals International Gmbh | Oral cephalotaxine dosage forms |
| CN103351390A (zh) * | 2007-11-21 | 2013-10-16 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4 抑制剂 |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| US20150050626A1 (en) * | 2013-03-15 | 2015-02-19 | Dart Neuroscience, Llc | Systems, Methods, and Software for Improving Cognitive and Motor Abilities |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3607885A (en) * | 1968-08-15 | 1971-09-21 | Universal Oil Prod Co | Preparation of lactones such as substituted delta valerolactones |
| US3644426A (en) * | 1969-08-15 | 1972-02-22 | Universal Oil Prod Co | Preparation of delta valero-lactones |
| US3814771A (en) * | 1970-11-19 | 1974-06-04 | T Shen | 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones |
| US3718743A (en) * | 1970-11-19 | 1973-02-27 | Merck & Co Inc | 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones in compositions and methods for treating pain, fever and inflammation |
| JPS51131870A (en) * | 1975-01-20 | 1976-11-16 | Yoshitomi Pharmaceut Ind Ltd | A process for preparing novel amide compounds |
| JPS52156859A (en) * | 1976-06-18 | 1977-12-27 | Yoshitomi Pharmaceut Ind Ltd | Heterocyclic amide derivatives |
| US4616089A (en) * | 1983-08-03 | 1986-10-07 | University Of California | Synthetic anti-inflammatory derivatives of manoalide |
| JP3101053B2 (ja) * | 1992-02-07 | 2000-10-23 | 株式会社共立 | 新規化合物及び該化合物を含有するマツノザイセンチュウ殺線虫剤 |
| DE19603477A1 (de) * | 1996-01-31 | 1997-08-07 | Klaus Dr Med Reuter | Tumormittel |
| KR20000070396A (ko) * | 1997-01-22 | 2000-11-25 | 고토 기치 | 액정 화합물, 이를 함유하는 액정 조성물 및 이를 함유하는액정 디스플레이 장치 |
-
1999
- 1999-09-09 WO PCT/CA1999/000819 patent/WO2000014083A1/en not_active Ceased
- 1999-09-09 CA CA002343732A patent/CA2343732C/en not_active Expired - Fee Related
- 1999-09-09 DE DE69919179T patent/DE69919179T2/de not_active Expired - Lifetime
- 1999-09-09 AT AT99941351T patent/ATE272628T1/de active
- 1999-09-09 ES ES99941351T patent/ES2226422T3/es not_active Expired - Lifetime
- 1999-09-09 US US09/786,949 patent/US6458829B1/en not_active Expired - Lifetime
- 1999-09-09 AU AU55009/99A patent/AU757052B2/en not_active Ceased
- 1999-09-09 JP JP2000568841A patent/JP4979157B2/ja not_active Expired - Fee Related
- 1999-09-09 EP EP99941351A patent/EP1112262B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4126879B1 (en) | N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer | |
| Schiavone Panni et al. | Good clinical results with autologous matrix-induced chondrogenesis (Amic) technique in large knee chondral defects | |
| ES2778846T3 (es) | Moduladores heterocíclicos de transportadores de casete de unión a ATP | |
| Fang et al. | Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis | |
| Gomoll et al. | Triad of Cartilage restoration for unicompartmental arthritis treatment in young patients–meniscus allograft transplantation, cartilage repair, and osteotomy | |
| US6632836B1 (en) | Carbocyclic potassium channel inhibitors | |
| EP1126849B1 (en) | Heterocyclic potassium channel inhibitors | |
| US6194458B1 (en) | Benzamide potassium channel inhibitors | |
| BR9507561A (pt) | Ligação de E-selectina P-selectina ou L-selectina para sialil-lewis X ou sialil-lewis A | |
| RU2015119635A (ru) | Соединения бензоксазолинона с избирательной активностью в потенциал-зависимых натриевых каналах | |
| EA027828B1 (ru) | Противовирусные соединения | |
| JP2006514989A5 (enExample) | ||
| RU2006125377A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| CA2322008A1 (en) | 2'-fluoronucleosides | |
| CA2472713A1 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| EA200200509A1 (ru) | Новые производные бензоимидазола, используемые в качестве антипролиферативного средства | |
| WO2004056786A3 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| MXPA01011517A (es) | Nucleosidos de 4'-c-etinil-purina. | |
| JP2008506714A5 (enExample) | ||
| JP2006508069A5 (enExample) | ||
| Qi et al. | Osteoarthritis prevention and meniscus regeneration induced by transplantation of mesenchymal stem cell sheet in a rat meniscal defect model | |
| JP2008543781A5 (enExample) | ||
| DK0791004T3 (da) | Acylerede benzylglykosider som inhibitorer af glat-muskelceller-proliferation | |
| Dai et al. | Meniscal injury in children: long-term results after meniscectomy |